PsiOxus Therapeutics has a highly experienced executive team.
Chief Executive Officer: Dr John Beadle
Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John's leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.
Chief Operating Officer: Priya Mande
Priya Mande has over 25 years' experience in the pharmaceutical and biotech sector, 12 of which were at Glaxo Wellcome and GlaxoSmithKline where she was most recently senior Director of R&D Business Projects. She has held a variety of roles across research, development, project management, finance and business strategy & operations. She was previously at PowderMed responsible for delivery of the vaccine immunotherapeutic portfolio. Priya was the Vaccine Research Project Leader for Influenza at Pfizer before becoming Chief Operating Officer of Hybrid BioSystems in 2009. Priya studied Applied Biochemistry at Brunel University, has a Diploma in Company Direction from the Institute of Directors and received her MBA with distinction from the London Business School.
Chief Development Officer: Dr Charles Morris
Dr Charles Morris is a Medical Oncologist with over 20 years of cancer drug development experience in the pharmaceutical and biotechnology industries. Having gained clinical and research experience at The Christie Hospital in Manchester, UK, he joined Zeneca (later AstraZeneca) Pharmaceuticals where he was solved in the development of a number of oncology agents including fulvestrant and gefitinib. Having gained experience across all phases of drug development, he later joined Cephalon where he was Vice President Clinical Research, Oncology, helping to secure approvals for bendamustine in two hematology-oncology indications. He later became Chief Medical Officer at Allos Therapeutics - which was acquired by Spectrum Pharmaceuticals in 2012 - and then Chief Development Officer at ImmunoGen Inc., leading the development of their proprietary pipeline of antibody drug conjugates. Dr Morris is a graduate of Sheffield University Medical School and is a Member of the Royal College of Physicians.
Chief Medical Officer: Dr Hilary McElwaine-Johnn
Dr Hilary McElwaine-Johnn is a Physician with over 20 years' experience in drug development, most recently within venture capital backed biotech companies. Prior to joining PsiOxus in December 2015, Hilary was Chief Medical Officer at Vantia Therapeutics from 2008. Hilary has experience with small molecules and biologics across multiple phases of development in a broad range of therapeutic areas including immunotherapeutics and cancer vaccines. From 2004, Hilary was Vice President Clinical at PowerMed, responsible for clinical development of DNA based vaccines for influenza, chronic viral diseases and cancer, prior to its successful acquisition by Pfizer.
Hilary is a graduate of Imperial College London and St Mary's Hospital Medical School and is a Member of Royal College of Physicians and of the Faculty of Pharmaceutica Medicine.
Chief Scientific Officer: Dr Brian Champion
Dr Brian Champion was previously Executive Director and Head of Immunology for Pfizer's Vaccine Immunotherapeutics Research Unit in La Jolla, California. In this role Brian led the immunology team providing expertise and immunoassays for all Pfizer vaccine projects, including therapeutic T-cell focused vaccines for cancer, antibody focused vaccines for several different diseases as well as several prophylactic infectious disease vaccines. He was also a member of the leadership team as well as Program Lead for an anti-IgE therapeutic vaccine for allergy/asthma. Prior to this role, Brian was Site Head for Pfizer Vaccine Research in the UK. Before joining Pfizer, Dr Champion was Chief Scientific Officer for Lorantis and Celldex, Cambridge, developing protein and DNA-based, antigen-specific immunotherapeutic approaches to a variety of immunological diseases, including therapeutic vaccines and immunotherapeutic biomolecule approaches for cancer, infectious diseases, allergies and autoimmune disorders. Prior to Lorantis, he was with Glaxo and GlaxoWellcome (UK and USA) for 13 years, focusing primarily on target discovery and validation research for autoimmune, allergic and bone disorders.
Chief Business Officer: Karen LaRochelle
Karen J LaRochelle has broad biopharmaceutical strategy and collaborations experience. She spent 20 years with Bristol-Myers Squibb serving as Global Head of Negotiations and Head of Business Development in China, following earlier positions in alliance management, strategy, analysis and finance. Karen also lead a successful consultancy providing business development expertise to leading biotechnology companies including Exelixis and Chase Pharmaceuticals. Karen has successfully negotiated and executed transactions with biotechnology, pharmaceutical, technology and international companies, several in excess of $1 billion, across therapeutic areas including oncology, neuroscience, virology and cardiovascular. Karen received her MBA from Columbia University and a BS in Industrial Engineering from Lehigh University. She leads the Business Development Advisory Board of New Jersey's Biotechnology Council (BioNJ), and currently serves on the Lehigh University Engineering Advisory Board.